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Purpose: Diabetic peripheral neuropathy (DPN) is
the commonest cause of neuropathy worldwide, and
its prevalence increases with the duration of diabetes.
It affects approximately half of patients with diabetes.
DPN is symmetric and predominantly sensory, starting
distally and gradually spreading proximally in a glove-
and-stocking distribution. It causes substantial morbid-
ity and is associated with increased mortality. The
unrelenting nature of pain in this condition can
negatively affect a patient's sleep, mood, and function-
ality and result in a poor quality of life. The purpose of
this review was to critically review the current liter-
ature on the diagnosis and treatment of DPN, with a
focus on the treatment of neuropathic pain in DPN.
Methods: A comprehensive literature review was
undertaken, incorporating article searches in electronic
databases (EMBASE, PubMed, OVID) and reference
lists of relevant articles with the authors' expertise in
DPN. This review considers seminal and novel re-
search in epidemiology; diagnosis, especially in relation
to novel surrogate end points; and the treatment of
neuropathic pain in DPN. We also consider potential
new pharmacotherapies for painful DPN.
Findings: DPN is often misdiagnosed and inad-
equately treated. Other than improving glycemic control,] 2018there is no licensed pathogenetic treatment for diabetic
neuropathy. Management of painful DPN remains chal-
lenging due to difﬁculties in personalizing therapy and
ascertaining the best dosing strategy, choice of initial
pharmacotherapy, consideration of combination therapy,
and deciding on deﬁning treatment for poor analgesic
responders. Duloxetine and pregabalin remain ﬁrst-line
therapy for neuropathic pain in DPN in all 5 of the major
published guidelines by the American Association of
Clinical Endocrinologists, American Academy of Neurol-
ogy, European Federation of Neurological Societies, Na-
tional Institute of Clinical Excellence (United Kingdom),
and the American Diabetes Association, and their use has
been approved by the US Food and Drug Administration.
Implications: Clinical recognition of DPN is imper-
ative for allowing timely symptom management to
reduce the morbidity associated with this condition.
(Clin Ther. 2018;]:]]]–]]]) & 2018 Elsevier HS Jour-
nals, Inc. All rights reserved.
Key words: diabetes, diagnosis, epidemiology, neu-
ropathy, pharmacotherapy.1
Clinical TherapeuticsINTRODUCTION
Diabetes has reached epidemic proportions world-
wide, with International Diabetes Federation estimates
suggesting a prevalence of 425 million people world-
wide in 2017, rising to 628 million by 2045.1 This rise
will be accompanied by an increase in the prevalence
of the complications of diabetes.2 DPN is the most
common cause of neuropathy worldwide, and is
estimated to affect around half of people with
diabetes.3,4 It causes considerable morbidity, impairs
quality of life, and increases mortality.5,6 Indeed,
approximately one fourth of the US health care
expenditure on diabetes is spent on DPN.7
Diabetic neuropathy refers to a collection of clin-
ically diverse disorders affecting the nervous system,
with differing anatomic features, clinical courses, and
phenotypes. The common underlying pathophysiology
is a consequence of hyperglycemia and microangiop-
athy.8 The commonest form is distal symmetric
sensorimotor polyneuropathy9; however, most body
systems can be affected through involvement of the
autonomic nerves. Despite the considerable, health
care–related economic burden and effect on quality
of life in DPN, treatment options are limited and
prevention remains the key goal.10 The purpose of this
review was to critically review the current literature on
the diagnosis and treatment of DPN, with a focus on
the treatment of neuropathic pain in DPN.MATERIALS AND METHODS
A comprehensive literature review was undertaken,
incorporating article searches in electronic databases
(EMBASE, PubMed, OVID) and reference lists of
relevant articles with the authors' expertise in DPN.
Articles published from inception of databases to
December 2017 were identiﬁed. Data from articles
that were felt not relevant by authors with the
guidance of the senior reviewers (R.A.M., U.A.) were
excluded from the review.RESULTS
Databases searches were undertaken and 188 papers
were cited in the ﬁnal manuscript. Authors excluded
studies that were not considered relevant to the aims
of this article. Further appraisal of selected articles
were undertaken and any relevant explanatory data
from said articles were included in the present review
as descriptive prose.2Epidemiology
Epidemiologic studies of diabetic neuropathy have
provided heterogeneous results, owing to different pa-
tient populations, deﬁnitions of neuropathy used, and
methods of assessments. Prediabetes is also associated
with neuropathy.11 In the San Luis Valley cohort,12 the
prevalence of peripheral neuropathy in patients with
diabetes was 25.8%, as compared to 11.2% in subjects
with impaired glucose tolerance (IGT) and 3.9% in
control subjects. The MonItoring trends and
determinants in CArdiovascular/Cooperative Research
in the Region of Augsburg (MONICA/KORA)13
investigators found the prevalence of neuropathic pain
to be 13.3% in patients with diabetes versus 8.7%,
4.2%, and 1.2% in subjects with IGT, impaired fasting
glucose, and controls, respectively. PROMISE
(Prospective Metabolism and Islet Cell Evaluation)14
followed up patients longitudinally who were at risk for
developing diabetes. At 3 years, the prevalence of
neuropathy (as assessed using the Michigan
Neuropathy Screening Instrument) was 50% in
patients who developed diabetes, 49% in those with
prediabetes, and 29% in controls.15
In a Spanish study, the reported prevalence of DPN
in primary care was 21% compared to 27% in-
hospital.16 The Rochester Neuropathy Study evaluated
data from 380 participants16; DPN, diagnosed using a
multifaceted approach, including the neuropathy
symptom score, neuropathy disability score, and nerve
conduction studies, was found in 66% and 59% of
patients with type 1 and 2 diabetes, respectively.
Importantly, approximately 10% of participants had
a nondiabetic etiology of the neuropathy.16
A large-scale, multicenter study (N ¼ 6500) re-
vealed DPN (based on questionnaire and examina-
tion) in 28.5%.4 A community-based study in
~15,000 patients with diabetes showed that 34% of
patients had symptoms of painful neuropathy, with an
increased risk in patients with type 2 diabetes, women,
and people of South Asian origin.17
The prevalence of DPN is considered to be low in
patients with early type 1 diabetes; however, among
participants in the Diabetes Control and Complica-
tions Trial (DCCT), the prevalences of abnormal
neurologic exam results were almost 20% in those
on conventional treatment and almost 10% in those
on intensive treatment, after ~5 years of follow-up.18
In the EURODIAB IDDM complications study,19
which evaluated over 3000 patients across 16Volume ] Number ]
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prevalence, which rose by 23.5% after 7 years. The
risk factors for the development of neuropathy
included age, duration of diabetes, poor glycemic
control, elevated low-density lipoprotein cholesterol
and triglycerides, hypertension, obesity, and
smoking.19 The EDIC (Epidemiology of Diabetes
Interventions and Complications) study, following
up patients up for 13 years after the initial 6.5 years
of the DCCT,8 showed an initial 64% reduction in the
risk for DPN in those on intensive compared to
conventional treatment during the DCCT period and
a 30% risk reduction was maintained in the follow-up
EDIC study period.8
More recently, the prevalence of DPN in youth with a
shorter duration of diabetes has been reevaluated. In
SEARCH (the Search for Diabetes in Youth Study),20 a
cohort of young people (aged o20 years) who had a
duration of diabetes of over 5 years were evaluated using
the Michigan Neuropathy Screening Instrument.21 Data
from 1374 patients with type 1 diabetes and 258 with
type 2 diabetes were studied, revealing prevalence rates of
DPN of 7% and 22%, respectively,21 suggesting an
excessive burden of DPN even in adolescents.
Pathogenetic Treatments
Numerous pathogenetic treatments that target the
underlying molecular and cellular mechanisms involved
in DPN, including aldose reductase inhibitors, benfoti-
amine, and protein kinase C inhibitors, have undergone
clinical trials over the past 4 decades.10 All have failed in
Phase III clinical trials, and none have been approved by
the US Food and Drug Administration (FDA) as disease-
modifying treatments for DPN.22,23 Multiple reasons
have been cited for this failure. In part, the end points
selected, including composite clinical scores and quanti-
tative sensory testing (QST), which relies on patients'
responses, are deemed to be subjective24 and prone to
high variability, and even objective measures such as
neurophysiology have been shown to have high
interobserver variability.25–28 It is now also evident that
the rate of DPN progression is slower than predicted,23 in
part due to concomitant use of routine therapies such as
angiotensin-converting enzyme inhibitors,29 and therefore
trials need to be of longer duration.
Glycemic Control
Glycemic control has been shown to prevent or
delay the progression of neuropathy in patients with] 2018type 1 diabetes.30 The Pittsburgh Epidemiology of
Diabetes Complications Study suggested that duration
of diabetes, HbA1c, smoking status, and high-density
lipoprotein cholesterol are associated with
neuropathy.31,32 The Wisconsin Epidemiologic Study
of Diabetic Retinopathy reported a 20% decrease in
the prevalence of DPN for a 2% decrease in HbA1c
over 4 years of follow-up.33 In DCCT, HbA1c values
were 7.4% in the intensive group and 9.1% in the
conventional group, and the risk reduction for incident
DPN with intensive glucose control was 64% after 6.5
years of follow-up.8 By the 5th year of the EDIC study,
despite HbA1c values in the 2 groups being similar
(8.1% vs 8.2%), the prevalences of DPN and cardiac
autonomic neuropathy remained signiﬁcantly lower in
patients who had been on intensive therapy compared
to standard therapy during DCCT.34 This phenomenon
has been termed metabolic memory.
In type 2 diabetes, the evidence for the role of
improved glycemic control in slowing the progression
of neuropathy in patients is limited.35–37 ACCORD
(Action to Control Cardiovascular Risk in
Diabetes )36 showed a signiﬁcant reduction in loss of
sensation to light touch, which was only 1 of 4
neuropathy end points after a follow-up of 5 years.
It should be noted that the intensive glucose-lowering
regimen was associated with increased mortality
(hazard ratio ¼ 1.22; 95% CI, 1.01–1.46; P ¼ 0.04),
suggesting harm associated with tight glycemic control,6
and self-reported DPN conferred a higher risk for
mortality in the intensive glycemic control group than
in those with a higher HbA1c and those on aspirin.
38
Lipids
There is an association between plasma triglycerides/
remnant lipoproteins and the risk for DPN.19 In animal
models, treatment with speciﬁc fatty acids, such as
docosahexaenoic acid, have been shown to exhibit a
protective effect and potentially even can reverse DPN.39
It has been suggested that cholesterol-lowering treatments
(statins and ezetimibe)40,41 and triglyceride-lowering treat-
ments (ﬁbrates)40 may reduce the progression and severity
of DPN. Well-planned randomized trials are needed to
evaluate the impact of intensive plasma lipid normaliza-
tion on DPN.
Diet and Lifestyle Interventions
In patients with IGT, lifestyle intervention could
arrest the underlying process that leads to neuropathy.3
Clinical TherapeuticsThe Diabetes Prevention Program study42
demonstrated that lifestyle changes and treatment
with metformin reduced the prevalence of diabetes
in those with IGT. Lifestyle intervention may also be
effective in preventing DPN, as shown in the IGT
Causes Neuropathy study,43 in which diet and
exercise counselling in subjects with IGT resulted in
increased intraepidermal nerve ﬁber density (IENFD)
and an improvement in neuropathic pain.Weight Loss
Experimental studies have shown that incretin-
based therapies have valuable effects on diabetic
complications, independent of their glucose-lowering
abilities, mainly mediated by their antiinﬂammatory
and antioxidative stress properties.44 However, in a
pilot study in patients with type 2 diabetes and mild to
moderate DPN, 18 months of treatment with
exenatide, compared with glargine, had no effect on
neuropathy.45
In a meta-analysis of data from 10 studies, there
was greater remission and lower risks for micro-
vascular and macrovascular disease and mortality in
the bariatric surgery group as compared to a non-
surgical treatment group in patients with type 2
diabetes after at least 5 years of follow-up.46 In a
study of bariatric surgery in patients with and withoutTable I. A summary of the common tests used to asses
Test Advantage
NCS Sensitive, speciﬁc, and
reproducible and easily
standardized
M
gold standard technique O
NDS Good predictor for risk for
ulceration
D
QST Reproducible and reliable S
Skin biopsy Gold Standard, reliable and
reproducible
In
CCM Rapid, reproducible, non-invasive. M
Can detect small ﬁber damage and
track progression.
CCM ¼ corneal confocal microscopy; NCS ¼ nerve conduct
quantitative sensory testing.
4diabetes, there were improvements in body mass
index, systemic inﬂammation, metabolic parameters,
and small nerve ﬁbers, as measured by corneal
confocal microscopy (CCM).47
Micronutrient deﬁciencies after bariatric surgery
are associated with an acute neuropathy,48,49 and
longer longitudinal studies that accurately phenotype
neuropathy are required to delineate potential risk
factors for this condition.
Diagnosis of DPN
The American Diabetes Association's position state-
ment on diabetic neuropathy (2017) advises that the
early recognition of neuropathy and initiation of
appropriate management are essential to the manage-
ment of patients with diabetes.50 Alternative etiologies
of neuropathy should be actively diagnosed and treated.
These include chronic inﬂammatory demyelinating
polyneuropathy, B12 deﬁciency, hypothyroidism, and
uremia, which may concomitantly occur in diabetes.51
The tests frequently used to diagnose DPN have been
listed in Table I, along with their advantages &
disadvantages and type of nerve ﬁber they assess.
Screening
Patients with type 2 diabetes mellitus should be
screened annually from diagnosis, and those with type
1 diabetes, after 5 years of diagnosis.50 People withs neuropathy.
Disadvantage Type of Nerve
ust be done by trained
professional.
Large ﬁber
nly assesses large ﬁber damage.
oes not detect sub-clinical large
ﬁber damage.
Large and small
ﬁber
ubjective Large and small
ﬁber
vasive procedure. Needs
specialized laboratory service.
Small ﬁber
ust be done by trained
professional.
Small ﬁber
ion studies; NDS ¼ neuropathy disability score; QST ¼
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neuropathy if symptoms are present.50
Assessment
The assessment of patients for DPN should include
a careful and focused history. Symptomology of
neuropathy will differ according to the type of nerve
ﬁber involvement. Patients with large ﬁber dysfunc-
tion may experience numbness, tingling, or poor
balance. Small ﬁber neuropathy (SFN) may present
with neuropathic pain described as burning, stabbing,
or electric shocks. Pain is the trigger for patients to
seek medical care in 25% of patients diagnosed with
DPN.13,52
Many patients may be asymptomatic, and thus
examination is key to the diagnosis. A bedside test
should be employed for both small and large ﬁber
neuropathy, such as the neuropathy disability score
(NDS), which is a validated reliable and reproducible
screening tool that can also assess the severity of
neuropathy. The NDS consists of testing sensory
modalities, which include pain sensation (pinprick),
temperature perception (using hot and cold rods), and
vibration (128-Hz tuning fork), all scored as either
normal (0) or reduced/absent (1). Abbott et al53
showed that a neuropathy disability score of 46/10
was an independent risk factor for new foot ulcers. All
patients should undergo annual 10-g monoﬁlament
and pedal pulse evaluation to assess the risk for foot
ulcers.50 The key is that the 10-g monoﬁlament should
not be used to diagnose or exclude DPN as it detects
only advanced neuropathy. Indeed, in a recent
systematic review it was shown to have a very poor
diagnostic utility, with a sensitivity of 88% but a
speciﬁcity of only 55%, when nerve conduction was
used to diagnose DPN.54 The alternative 1-g
monoﬁlament may, however, be better for detecting
earlier neuropathy.55 The assessment of SNF remains
a particular challenge, especially in diabetic
neuropathy.56
DPN is common, and the diagnosis of DPN begins
with a careful history and examination of sensory and
motor symptoms and signs. The quality and severity
of neuropathic pain, if present, should be assessed
using a validated method that is reproducible, such as
the Michigan Neuropathy Screening Instrument. Ex-
amination within a clinic setting should include
inspection of the feet and evaluation of reﬂexes and
sensory responses to vibration, light touch, pinprick,] 2018and the 10g monoﬁlament. The exact pathophysio-
logic mechanisms of DPN remain to be elucidated,
and treatments targeted at the natural history and
pathophysiologic mechanisms of DPN are urgently
required.
Diagnostic Definition
The Toronto Diabetic Neuropathy Expert group57
classiﬁes DPN as:1. Conﬁrmed DPN—abnormal nerve conduction and
a symptom or sign of neuropathy;2. Probable DPN—2 or more of the following signs or
symptoms: neuropathic symptoms, decreased distal
sensation, or decreased/absent ankle reﬂexes; or3. Possible DPN—any of the following symptoms:
decreased sensation, positive neuropathic sensory
symptoms (eg "asleep numbness," prickling/stab-
bing, burning, or aching pain), predominantly in
the toes, feet, or legs; OR signs, including symmet-
ric decrease of distal sensation or decreased/absent
ankle reﬂexes.
The ADA's position statement does not recommend
the use of neurophysiology for the diagnosis of typical
DPN, and this testing modality should be reserved for
patients in whom atypical features are present or the
diagnosis is unclear.
Neuropathy Symptoms
Questionnaires are a subjective method to assess
and quantify the severity of neuropathic symptoms
and pain. The McGill Pain Questionnaire58 is widely
used to evaluate neuropathic pain. Other
questionnaires speciﬁcally developed for neuropathic
pain quantiﬁcation are the Brief Pain Inventory,59
Neuropathic Pain Questionnaire,60 Neuropathic Pain
Symptom Inventory,61 and the Doleur Neuropathique
4.62 The Neuropathic Symptom Proﬁle has been
validated to detect and stage the severity of
neuropathy.63 The Brief Pain Inventory, Neuropathic
Pain Questionnaire, Neuropathic Pain Symptom
Inventory and NSP are all validated self-
administered questionnaires.
Quantitative Sensory Testing
QST, which includes a thermal threshold assess-
ment for cold sensation (A-δ ﬁbers) and warm sensa-
tion (c ﬁbers), assesses small ﬁber dysfunction and5
Clinical Therapeuticstherefore can detect early neuropathy, but is highly
subjective. However, QST is a sensitive method of
detecting SFN, particularly in those patients with
normal nerve conduction study results,64 and may
be used where no deﬁnitive quantitative structural
assessment of small nerve ﬁbers (skin biopsy or CCM)
can be undertaken.
Also, vibration perception threshold, assessed using
a biothesiometer, correlates with the severity of DPN,
and a vibration perception threshold of 425 V is a
strong predictor of foot ulceration.65
Nerve Conduction Studies
Nerve conduction studies (NCSs) are commonly
used to assess the severity of DPN and are considered
to be sensitive and speciﬁc for DPN.66 Interestingly,
Dyck et al24 compared NCS to individual physicians'
clinical diagnosis of DPN and found that clinician's
diagnoses were excessively variable and frequently
inaccurate, with an overestimation of DPN. Vinik
et al67 conducted a study in 205 patients with both
type 1 and 2 diabetes and mild DPN and showed that
sural nerve conductivity correlated well with the
severity of DPN. However, NCSs evaluate only large
myelinated nerve ﬁbers and cannot detect an early
SFN as commonly seen in prediabetes and short-
duration diabetes. The ADA's position statement
does not advocate the routine use of NCS, and it
should be reserved for patients with atypical features
in whom the diagnosis is unclear.50
Skin Biopsy
Skin biopsy enables direct visualization of thinly
myelinated and nonmyelinated nerve ﬁbers that are
the earliest to be affected in DPN. Skin biopsy can be
used to diagnose SFN.68 The European Federation for
Neurological Societies' guidance recommends a punch
skin biopsy at the distal leg or proximal thigh for the
diagnosis of SFN.69 The assessments of intraepidermal
nerve ﬁbers and IENFD are currently advocated in
clinical practice in the United States43 and are
recommended as an end point in clinical trials.23
Pittenger et al70 showed a reduction in IENFD in
patients with SFN, with a sensitivity between 74%
and 87.5%, and that IENFD was inversely correlated
with QST. An inverse correlation has also been shown
between IENFD and the duration of diabetes,
neurologic impairment score, and results of sensory
evaluation.70,716Novel Surrogate Imaging Markers of DPN
Corneal Confocal Microscopy
Over the past 2 decades, the signiﬁcance of evalu-
ating corneal nerve morphology as a surrogate marker
for peripheral neuropathies has been established.
CCM has been suggested as a surrogate end point
for the assessment of DPN, as it allows direct visual-
ization of peripheral nerves and is a rapid, non-
invasive, and objective technique,72,73 with high
sensitivity and speciﬁcity to diagnose early nerve ﬁber
damage23 and repair.74 Several studies have shown
that CCM is highly correlated with IENFD loss23 and
is comparable to the diagnostic ability of skin
biopsy.75,76 A number of parameters are used to
quantify the corneal sub-basal nerve plexus and
include corneal nerve ﬁber length, corneal nerve
branch density, and corneal nerve ﬁber density.
CCM has been extensively used to identify small
nerve ﬁber damage in a range of peripheral neuro-
pathies, including DPN,77,78 HIV neuropathy,79
chemotherapy-induced peripheral neuropathy,80
CIDP,81 Fabry disease,82 and idiopathic SFN.83
CCM can detect subclinical small nerve ﬁber
damage in patients with IGT84 and has been shown
to predict the development of DPN85 and the end
points of foot ulceration and Charcot foot.86 CCM
may be an ideal technique to monitor the progression
of DPN, as it is noninvasive and hence reiterative.87Optical Coherence Tomography
Optical coherence tomography is a noninvasive,
reproducible ophthalmic imaging technique that was
recently introduced as a surrogate end point for the
assessment of retinal nerve ﬁber loss in neurologic
conditions.88,89 Retinal nerve ﬁber layer (RNFL)
thinning is reported in patients with DPN associated
with the severity of neuropathy, particularly in pa-
tients with a higher risk for foot ulceration.90 Previous
studies have suggested that RNFL loss in patients with
diabetes may be independent of diabetic retinopathy
and represents a distinct type of neuropathy.91,92
Measuring RNFL thickness has also been suggested
as a potentially useful means to assess and monitor
axonal loss in patients with DPN, as RNFL thinning
was greater in patients with DPN compared to those
without DPN over the course of 4 years.93 However,
larger-scale, longitudinal prognostic and interven-
tional studies using optical coherence tomography asVolume ] Number ]
Z. Iqbal et al.a surrogate marker are required before routine use of
this modality can be recommended.
The use of optical coherence tomography as a
possible diagnostic modality is still in its infancy and
requires longitudinal studies alongside established
biomarkers, such as electrophysiology and skin bi-
opsy. CCM has a wealth of research, particularly in
DPN. However, the availability of CCM as a diag-
nostic modality is limited due to a lack of expertise
in its use as a surrogate marker in peripheral
neuropathies.
Symptomatic Treatment of DPN
Neuropathic pain is a debilitating feature of DPN
resulting in signiﬁcant morbidity.94 Current guidelines
advocate the use of therapies targeting the symptoms of
painful DPN, particularly as there is a lack of treatments
targeting the pathogenetic mechanisms. Although
measures such as tight glycemic control may prevent
the progression of diabetic neuropathy, there is no
evidence that improved glycemic control improves pain
in DPN. Moderate improvements in pain are considered
to be ~30% to 50% pain relief, whereas 450% pain
relief is considered a good outcome.95 A recent
systematic review concluded that duloxetine,
venlafaxine, pregabalin, oxcarbazepine, tricyclic
antidepressants (TCAs), atypical opioids, and
botulinum toxin were more effective than placebo for
relieving neuropathic pain, but quality of life was poorly
reported. Studies were however short term and drugs
had substantial discontinuation rates of ~10%.96
The limited beneﬁt of any one agent alone reﬂects
the complex etiologic basis of neuropathic pain. Thus,
there is an increasing recognition that "one size does
not ﬁt all," and rather than having an agnostic
approach (ie, blindly trying different therapies until
one works), we should consider better clinical pheno-
typing and targeted therapies.97 However, superﬁcial
clinical phenotyping in relation to symptomatology
has not been shown to improve the response to
therapy.98 More detailed phenotyping using QST
has shown that patients with an irritable nociceptor
(IN) phenotype (n ¼ 31) compared to a non-IN
phenotype (n ¼ 52) had a signiﬁcantly greater
response to oxcarbazepine and a reduced overall
number needed to treat (NNT) (6.9 vs 3.9).99 In a
smaller-scale study, the relative efﬁcacy of 5%
lignocaine was assessed in 15 patients with IN and
25 patients with non-IN, a greater effect on pain] 2018paroxysms and deep aching pain was found in those
with IN.100 We have also demonstrated preclinical
evidence on the physiology and pharmacology of rate-
dependent depression of the spinal H-reﬂex as a
marker for spinal disinhibition in painful diabetic
neuropathy,101 and recently translated the use of
rate-dependent depression as a biomarker of spinally
mediated pain to a personalized-medicine approach in
the treatment of painful DPN.102 In this section, we
consider the current pharmacologic treatments for
alleviating pain in DPN, the most frequently used of
which are highlighted in Table II.
Antidepressants
Neurologic pathways implicated in mood disorders
share neurotransmitters with pathways associated
with pain processing.103 It is therefore not surprising
that there is a dual utility in alleviating neuropathic
pain.
Tricyclic Antidepressants
The precise mechanism of action of TCAs in
analgesic efﬁcacy is unclear, but they are thought to
indirectly modulate the opioid system in the brain via
serotonergic and norepinephrine neuromodulation,
among other properties.104–106 TCAs require up-titra-
tion to effective doses, often over a period of 6 to 8
weeks before reasonable effects are noted; hence,
compliance may sometimes be compromised.107 A
meta-analysis by Rudroju et al108 concluded that
amitriptyline was the least effective but a well-
tolerated agent compared to other antidepressant
agents used to treat painful DPN. In a joint report
on painful DPN from the American Academy of
Neurology, the American Association of
Neuromuscular and Electrodiagnostic Medicine, and
the American Academy of Physical Medicine and
Rehabilitation, published in 2011, it was concluded
that amitriptyline has the greatest efﬁcacy among the
TCAs.109 Despite studies showing the efﬁcacy of
imipramine,110 it was also concluded that there is
currently insufﬁcient evidence for the routine use of
imipramine.
TCAs remain as the ﬁrst- or second-line recom-
mendations in all 5 international guidelines on pain
management in DPN, with most citing amitriptyline as
the drug of choice among the TCAs (Table III). The
2017 position statement from the ADA stated that,
although effective for the treatment of neuropathic7
Table II. Commonly used therapies for painful diabetic peripheral neuropathy.
Drug Class Agent
Initial
Dose
Maintenance
Dose
Common
Adverse
Reactions Common Drug Interactions
Anticonvulsants Pregabalin 25–75 mg
TID
300–600 mg
daily
Dizziness Respiratory depression when
combined with opioids. Additive
effects on cognition and motor
function may occur when combined
with benzodiazepines, alcohol, or
opioids.
Somnolence
Headache
Weight gain
Nausea
Vomiting
Dry mouth
Gabapentin 100–300
mg TID
900– 3600
mg daily
Dizziness
Somnolence
Ataxia
Fatigue
Antidepressants Duloxetine 20–30 mg
once
daily
60–120 mg
once daily
Somnolence Avoid concurrent use with irreversible
MAOIs due to increased risk for
serotonin syndrome.
Dizziness
Headache Combination with tramadol may
lower seizure threshold.Nausea
Dry mouth Avoid use with ciproﬂoxacin.
Reduced
appetite
Venlafaxine 37.5 mg
once
daily
75–225 mg
once daily
Nausea Avoid use with MAOIs due to
increased risk for serotonin
syndrome.
Dizziness
Constipation Avoid use with linezolid (a weak
MAOI).
Dry mouth Concurrent use with other SNRIs,
SSRIs or serotonin receptor
agonists (eg, triptans) increases risk
for serotonin syndrome. Potential
use is advised with caution.
Weight loss
Constipation
Amitriptyline 10–25 mg
once
daily
25–100 mg
once daily
Abdominal
pain
Avoid MAOIs due to risk for serotonin
syndrome.
Fatigue Concurrent use with drugs prolonging
QT interval may predispose to
ventricular arrhythmias.
Headache Concurrent use with tramadol may
precipitate development of the
serotonin syndrome and should be
done with caution.
Dizziness Concurrent use with anticholinergic
drugs may potentiate their effects,
thus increasing the risk for paralytic
ileus.
Insomnia
Orthostatic
hypotension
(continued)
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Table II. (continued).
Drug Class Agent
Initial
Dose
Maintenance
Dose
Common
Adverse
Reactions Common Drug Interactions
Anorexia
Nausea
Urinary
retention
Constipation
Blurred vision
Mydriasis
Weight gain
Xerostomia
Somnolence
Opioids Tramadol 50 mg
QID
200– 400 mg
QID
Constipation Concurrent use with MAOIs and
linezolid increases risk for serotonin
syndrome.
Somnolence Combination therapy with SSRIs,
SNRIs, TCAs, or antipsychotics can
lower seizure threshold, leading to
convulsions. Combination use with
caution is advised.
Nausea
Headache
Dizziness
Tapentadol
(immedi-
ate
release)
50–100
mg 4–6
times
per day
600 mg daily Same as
above
Concurrent use with SSRIs or SNRIs
may increase risk for serotonin
syndrome. Use with caution is
advised.
Can take
700 mg
on ﬁrst
day
Concurrent use with MAOIs can result
in hypertensive crisis.
Use with enzyme inducers such as
rifampicin or St John's wort may
reduce efﬁcacy.
MAOIs ¼ monoamine oxidase inhibitors; SNRIs ¼ serotonin norepinephrine re-uptake inhibitors; SSRIs ¼ selective serotonin
re-uptake inhibitors; TCAs ¼ tricyclic antidepressants.
Z. Iqbal et al.pain, TCAs should be used with caution given
their higher-risk proﬁle, particularly in elderly
populations.50
Serotonin–Norepinephrine Reuptake Inhibitors
Two serotonin–norepinephrine reuptake inhibitors
are used in painful DPN, duloxetine and, to a lesser
extent, venlafaxine, which does not have FDA appro-
val for use in the treatment of painful DPN. A third
serotonin–norepinephrine reuptake inhibitor is des-
venlafaxine, which was evaluated in a single] 2018randomized, controlled trial and showed some efﬁ-
cacy.114 These drugs primarily exert their effect via
inhibiting serotonin and norepinephrine reuptake,
resulting in the excitation of inhibitory descending
pathways with alleviation of neuropathic pain.115
Duloxetine at both 40 mg and 60 mg has shown
efﬁcacy in treating painful DPN.116 A Cochrane
review including 8 trials (n ¼ 2728) showed that 60
mg of duloxetine daily was more efﬁcacious compared
with placebo, with a 50% pain reduction by 12 weeks
(NNT ¼ 5; 95% CI, 4–9).117 Tanenberg et al1189
Table III. Current guidelines for painful diabetic peripheral neuropathy.
Line of Treatment EFNS (2010)111 AAN (2011)109 NICE (2013)112 AACE (2015)113 ADA (2017)50
1st line Amitriptyline Pregabalin Amitriptyline Amitriptyline Duloxetine
Duloxetine Duloxetine SNRI Pregabalin
Pregabalin Pregabalin Pregabalin
Venlafaxine Gabapentin Gabapentin
Sodium valproate Clonidine
Gabapentin
2nd line Tramadol Amitriptyline Amitriptyline Tramadol TCA
Opioids Duloxetine Duloxetine Tapentadol Gabapentin
Sodium Valproate Pregabalin Topiramate
Venlafaxine Gabapentin Oxcarbazepine
Gabapentin Lidocaine 5%
Tramadol Capsaicin
Opioids
Capsaicin
3rd line Capsaicin
Tramadol
AACE ¼ American Association of Clinical Endocrinologists; AAN ¼ American Academy of Neurology; ADA ¼ American
Diabetes Association; EFNS ¼ European Federation of Neurological Societies; NICE ¼ National Institute of Clinical
Excellence (UK); SNRI ¼ serotonin norepinephrine reuptake inhibitor; TCA ¼ tricyclic antidepressant.
Clinical Therapeuticsshowed that duloxetine was noninferior to pregabalin
in treating painful DPN in patients exhibiting an
inadequate response to gabapentin. Duloxetine has a
superior safety proﬁle compared to amitriptyline,
owing to the comparably lower rates of
anticholinergic side effects. However, one study
found a 20% and 14% respective prevalence of
somnolence and constipation in a cohort of patients
treated with 60 mg of duloxetine daily.119 A post hoc
analysis of 3 pooled, double-blind, placebo-controlled
trials evaluating the use of duloxetine in older patients
(aged 465 years) advocated the tolerability and
efﬁcacy of this drug in the older population.120
Venlafaxine showed efﬁcacy in treating painful
DPN in a double-blind placebo controlled trial in
which pain-intensity visual analog scale (VAS) scores
were used as the primary outcome measure.121 A
Cochrane Collaboration systematic review122 of
venlafaxine for the treatment of neuropathic pain
reported an NNT of 3.1 (95% CI, 2.2–5.1), which
is comparable to that of amitriptyline.123 Venlafaxine
has shown superiority to duloxetine in some studies;
however, there is a lack of larger-scale trials showing
this effect.124 Additionally, it is important to note that10venlafaxine must be slowly weaned to reduce the
potential for adverse events,124 and it has not been
approved by the FDA for use in treating neuropathic
pain.
Anticonvulsants
Similarities in the mechanisms of neuropathic pain
and epilepsy led to the use of anticonvulsant medi-
cations in the treatment of painful DPN.125
Carbamazepine has been used efﬁcaciously in the
management of trigeminal neuralgia for many years;
however, a Cochrane Collaboration review found that
it had limited utility in the treatment of painful
DPN,126 and it is not recommend for painful DPN.
Similarly, in a recent Cochrane review, oxcarbazepine
showed little evidence for efﬁcacy in painful diabetic
neuropathy.127
α2δ Ligands
Gabapentin is a lipophilic analogue of γ-amino-
butyric acid that binds to the α2δ1 subunit of the
voltage-gated calcium channel on the presynaptic
membranes and reduces excitability of chieﬂy gluta-
minergic neurones.128Volume ] Number ]
Z. Iqbal et al.Backonja et al129 investigated its use in neuropathic
pain in a double-blind, placebo-controlled trial of
patients randomized to either gabapentin or placebo.
Signiﬁcant improvement in pain scores were seen 8
weeks after the start of treatment.129 A systematic
review of 35 studies (n ¼ 727) in patients with
unselected neuropathic pain concluded that
gabapentin was an effective agent in alleviating pain;
however, its effectiveness may be reduced if
administered at low doses.130 Rudroju et al108
compared the efﬁcacy and tolerability of 6 agents used
in the management of painful DPN in a meta-analysis
of data from 21 trials and concluded that gabapentin
provided a good balance between tolerability and
efﬁcacy for the treatment of painful DPN.
Pregabalin, another analogue of γ-aminobutyric
acid has higher potency and has been approved
by the FDA for use in treating painful DPN
based on several robust randomized, controlled trials
that have shown its efﬁcacy in the treatment of
painful DPN.131–133 Snedecor et al134 undertook a
comparative meta-analysis of data from studies of a
number of agents in the treatment of painful DPN and
found pregabalin to be the most efﬁcacious in
reducing pain VAS scores.
Somnolence is listed as a common side effect of
pregabalin, as studies in healthy volunteers have
shown that it enhances slow-wave sleep. A placebo-
controlled trial evaluated the efﬁcacy of pregabalin,
amitriptyline, and duloxetine in pain relief and the
effects on sleep.135 Duloxetine increased sleep
fragmentation, while pregabalin promoted sleep.135
These ﬁndings are in agreement with those from
previous studies showing that pregabalin improves
subjective sleep and quality of life in patients with
painful DPN.136,137 Side effects include edema and
mood disturbance, and it is important to warn
patients not to abruptly discontinue its use, as this
has been linked to the development of seizures,
cerebral edema, and encephalopathy.138 Both
gabapentin and pregabalin are commonly prescribed
as ﬁrst-line agents for treating painful DPN, and this is
indeed a reﬂection of the current recommendations.
COMBO-DN Study
The only 2 medications with both FDA and Euro-
pean Medicines Agency approval for use in the treat-
ment of painful DPN are pregabalin and duloxetine.
The COMBO-DN study was designed to compare the] 2018efﬁcacy and tolerability between high-dose monother-
apy and standard-dose combination therapy with
both pregabalin and duloxetine.139 This
multinational, randomized, double-blind, parallel-
group trial was conducted in patients with painful
DPN resistant to standard-dose monotherapy. After
randomization and elimination of noneligible patients,
173 received high-dose monotherapy with either
duloxetine 120 mg daily or pregabalin 600 mg daily,
and 170 patients received combination therapy with
duloxetine 60 mg daily and pregabalin 300 mg
daily.139 A 2-point reduction in the Brief Pain
Inventory score was the primary outcome measure;
no signiﬁcant difference was shown when comparing
the standard-dose combination therapy to the high-
dose monotherapy therapy in those who did not
achieve adequate pain relief on standard-dose
duloxetine or pregabalin.139
In a secondary analysis, duloxetine 60 mg was
found to be more efﬁcacious compared with pregaba-
lin 300 mg/day in the initial 8-week run in phase. To
date, this is the only head to head trial of duloxetine
and pregabalin. A further exploratory post hoc anal-
ysis of data from Combination vs. Monotherapy of
pregaBalin and duloxetine in Diabetic Neuropathy
(COMBO-DN) showed that high-dose monotherapy
was favorable in patients with severe pain, whereas
combination therapy was more beneﬁcial in patients
with moderate and mild pain.140 Also, patients who
received duloxetine (60 mg/d) as initial therapy had a
better response to combined duloxetine and
pregabalin for evoked or severe tightness and a
greater beneﬁt with high-dose duloxetine (120 mg/d)
for paresthesia–dysaesthesia.140,141
Other Anticonvulsants
The use of topiramate has been evaluated in several
placebo-controlled trials, with differing results. Raskin
et al142 randomized 323 subjects to topiramate versus
placebo and found a signiﬁcant 30% reduction in pain
VAS scores with topiramate.142 A recent smaller study
from Iran143 showed that gabapentin and topiramate
equally reduced pain scores.143 However, a Cochrane
Collaboration review of data from 3 placebo-
controlled, parallel-group trials showed that
topiramate lacks evidence of efﬁcacy in painful DPN.144
Lamotrigine is chemically unrelated to other anti-
epileptic agents. It is thought to exert its antiepileptic
effect via sodium channels. Lamotrigine has been11
Clinical Therapeuticsassessed in painful DPN. Eisenberg et al145 observed a
signiﬁcant reduction in the numeric pain scale in 83%
of patients randomized to lamotrigine compared to
73% receiving placebo, but this study was relatively
small-scale (n ¼ 59). In an analysis of data from 2
randomized trials, lamotrigine (300 and 400 mg daily)
showed inconsistent effects in DPN, and while it was
well tolerated,146 it cannot be advocated for use in
painful DPN.147
A double-blind, placebo-controlled trial of lacosa-
mide found it to be efﬁcacious compared to placebo;
however, the cohort receiving 600 mg daily had a
much higher withdrawal rate due to adverse reactions,
such as nausea, tremor, headache, and fatigue.148 The
efﬁcacy of lacosamide over placebo was also marginal,
and it is therefore currently not recommended for use
in painful DPN.147
Opioid Analgesia
Partial µ-Receptor Agonists
Tramadol is a centrally acting synthetic opioid that
is a nonselective agonist with afﬁnity at the µ-, δ-, and
κ-opioid receptors, with preferential afﬁnity for the µ-
receptor, and also inhibits norepinephrine and sero-
tonin reuptake.149 A Cochrane Collaboration review
found that the efﬁcacy of tramadol in neuropathic
pain was determined in small-scale, largely inadequate
studies with a potential risk for bias.149 Although data
from 3 of these trials were further analyzed in a meta-
analysis and showed an NNT for 50% pain reduction
of 4.4 (95% CI, 2.9–8.9),149 it still concluded that
there were insufﬁcient data of adequate quality to
provide convincing evidence that tramadol is effective
in relieving neuropathic pain.149 Anecdotally,
tramadol may be used to treat breakthrough pain in
combination with other neuropathic pain agents,
although its use in combination with TCAs and
serotonin–norepinephrine reuptake inhibitors is
cautioned due to the increased risk for serotonin
syndrome, with increased risks for confusion,
seizures, labile blood pressure, and, in extreme cases,
coma and death.
Tapentadol is similar to tramadol in its mechanism
of action. Schwartz et al150 conducted a 12-week
open-label study in 396 patients with DPN, which
demonstrated a 30% pain reduction in 65% of
patients and a 50% pain reduction in 34.9% of
patients.150 A subsequent 12-week study conﬁrmed
these earlier data, and in 2012 the FDA approved the12use of modiﬁed-release tapentadol for the treatment of
neuropathic pain.151
Opioid Agonists
There is increasing concern for opioid dependency,
especially during long-term use, despite the efﬁcacy of
opioids in treating neuropathic pain.152 A Cochrane
Collaboration review153 evaluated the use of
oxycodone modiﬁed release, morphine, levorphanol,
and methadone in the treatment of neuropathic pain
and found that, in studies lasting 12 weeks or less,
opioids exhibited a signiﬁcant analgesic effect
compared to placebo, but the results were subject to
bias due to relatively small sample sizes and short
duration of studies.153 Additional data are needed to
characterize long-term efﬁcacy and the safety proﬁle
of opioids in neuropathic pain.
Topical Medications
Topical treatments for painful DPN may be partic-
ularly useful for patients not tolerating conventional
systemic therapies, as there is a reduced prevalence of
adverse effects.154 Furthermore, the risk for drug–
drug interactions is also signiﬁcantly reduced, making
topical therapies more attractive for a growing
number of patients with multiple comorbidities and
polypharmacy.
Capsaicin is a naturally occurring alkaloid found in
red chili peppers. It works by selectively agonizing
the transient receptor potential vanilloid 1 (TRPV1)
receptor, which is expressed on small nerve ﬁbers.
Downstream signals from the TRPV1 receptor result
in the release of substance P and its subsequent
depletion, which causes a reduction of painful stimuli
conveyed to the CNS.155,156 The Capsaicin Study
Group conducted a double-blind, placebo-controlled
trial (n = 277) of 0.0075% topical capsaicin and
found a signiﬁcant reduction in pain, as measured by
physicians' global evaluation and a VAS scale.157
Capsaicin is currently recommended as third-line
therapy in the United Kingdom's National Institute
of Clinical Excellence guidelines and second-line by
the American Academy of Neurology for the
treatment of neuropathic pain. Its use is severely
limited by the frequency of application (4 times
daily) and burning pain frequently induced on
application. Of concern, capsaicin has been shown
to lead to a reduction in thermal nociception and total
denervation, with a putative increased risk for diabeticVolume ] Number ]
Z. Iqbal et al.foot ulceration, and is not recommended in the
treatment of painful DPN.158
Furthermore, currently not included in any pub-
lished guidance for painful DPN is the 8% capsaicin
patch, which was initially tested in patients with
postherpetic neuralgia. A recent review reported its
efﬁcacy in a number of neuropathies of varying
etiology and included data from a 12-week double-
blind trial in patients with painful DPN, in whom it
improved both pain and sleep quality signiﬁcantly; yet
the review, despite including a study on the use of
capsaicin in skin biopsies, failed to report on the
outcomes.159
Lidocaine plaster 5% applied for 18 h/d has been
shown to effectively provide relief in painful DPN and
has been extensively used in postherpetic neuralgia. A
systematic review of data from 38 studies found a
signiﬁcant pain reduction using the 5% lidocaine
patch that was comparable to those with amitripty-
line, capsaicin, gabapentin, and pregabalin.154 The
lidocaine patch was also found to be associated
with fewer and less clinically signiﬁcant side effects
compared to systemic agents.154 A meta-analysis
reported that the 5% lidocaine patch was as
efﬁcacious as pregabalin in treating painful DPN.134
Topical isosorbide dinitrate has been evaluated in
the treatment of painful DPN. Impaired nitric oxide
synthesis has been found to play a role in DPN
pathogenesis. The vasodilatory response to nitrogly-
cerin directly releases nitric oxide, suggesting a poten-
tial role for its use in patients with DPN.160 Alterations
of neuronal nitric oxide synthase in the dorsal root
ganglion cells and in the spinal cord may contribute
to spinal sensory processing, as well as to the
development of neuronal plasticity phenomena in the
dorsal horn of the spinal cord, as previously described
in experimental studies.160 Yuen et al161 found
signiﬁcant reductions in pain and intensity in a
double-blind trial recruiting 22 patients. Later,
Rayman et al162 described a case series of 18 patients
treated with glyceryl-trinitrate patches with localized
pain showing a reduction in pain scores. Topical
lidocaine and glyceryl-trinitrate patches may be used
in combination to provide 24-hour pain cover with
alternating 12-hour applications of each therapy.
Intravenous Lidocaine
IV lidocaine has been used in the treatment of pain
produced by nerve injury for many years. Major] 2018Gordon of the Royal Canadian Army Medical Corps
used IV procaine to successfully provide analgesia to
burn patients as early as 1943.163 Viola et al164 was the
ﬁrst group to evaluate the effectiveness of IV lidocaine
infusion, in a double-blind, placebo-controlled trial in
patients with intractable painful DPN refractory to
standard treatment. A randomized, placebo-controlled
trial of IV lidocaine infusion in 15 patients showed a
signiﬁcant analgesic effect, which persisted for up to 28
days.164 There were no signiﬁcant side effects of this
treatment, although this cohort was small. The efﬁcacy
of lidocaine seems to be due to several independent
modes of action targeting neuropathic pain. Lidocaine
modiﬁes sodium channel expression, reducing peripheral
nociceptive sensitization,165 and it also has anti-
inﬂammatory properties similar to those of
conventional anti-inﬂammatory drugs.166 Inﬂammatory
cytokines are thought to play a role in secondary
hyperalgesia and the sensitization of the CNS to
inappropriate pain signals.167
Emerging Therapies for Painful DPN
Virtually no new novel analgesics have been app-
roved by the FDA for the treatment of neuropathic
pain over the past 20 years. There are several emerging
treatments that may potentially shift the pharmacologic
paradigm in the treatment of neuropathic pain
(Table IV). Such targets include suppression of
glutaminergic neurotransmission,168 N-methyl-
D-aspartate receptor antagonism,169 angiotensin II
receptor type 2 antagonism, and presynaptic modula-
tion of cannabinoids170 and humanized anti–nerve
growth factor monoclonal antibodies.171
Dextromethorphan is an N-methyl-D-aspartate re-
ceptor antagonist that has been evaluated in Phase III
clinical trials for the treatment of painful DPN. In
addition, it also has properties of serotonin reuptake
inhibition. Administered as monotherapy, dextrome-
thorphan has limited bioavailability due to rapid
catabolism by hepatic cytochrome P-450 2D6. It must
therefore be administered with a potent P-450 2D6
inhibitor such as quinidine. Shaibani et al172 evaluated
2 doses of dextromethorphan/quinidine, 45/30 mg
and 30/30 mg, in a double-blind, placebo-controlled
trial (n ¼ 379) and showed that dextromethorphan/
quinidine was signiﬁcantly more efﬁcacious compared
with placebo, with a reasonable safety proﬁle.
Desvenlafaxine is the most potent metabolite of the
parent compound venlafaxine and has been evaluated13
Table IV. Emerging therapies for the treatment of painful diabetic peripheral neuropathy.
Drug Drug Class Developer
Dextromethorphan/quinidine
combination
Glutamate antagonist Avanir, New York, New York
EMA401 Angiotensin II type 2 receptor
antagonist
Novartis, East Hanover, New Jersey
Capsaicin, dermal patch (NGX-
4010)
Vanilloid-receptor agonist NeurogesX, San Mateo, California
Desvenlafaxine SR SNRI Wyeth, Madison, New Jersey
Lacosamide (SPM-927) Amino acid anticonvulsant Schwarz Pharma, Mequon, Wisconsin
Lamotrigine once daily Anticonvulsant GlaxoSmithKline, Research Triangle Park,
North Carolina
Oravescent fentanyl Opioid agonist Cephalon, Frazer, Pennsylvania
Tramadol ER Mu-opioid antagonist and SNRI TheraQuest Biosciences, Blue Bell,
Pennsylvania
GW-406381 COX-2 inhibitor GlaxoSmithKline
Cibinetide (ARA290) Peptide of erythropoietin Araim, Tarrytown, New York
Innate repair receptor and TRPV1
antagonist
COX ¼ cyclooxygenase; ER ¼ extended release; SNRI ¼ serotonin–norepinephrine reuptake inhibitor; SR ¼ sustained release;
TRPV1 ¼ transient receptor potential vanilloid 1.
Clinical Therapeuticsin patients with painful DPN.114,173 In a Phase III
multicenter, randomized placebo-controlled trial (n =
412), graduated doses of 200 and 400 mg/d desvenla-
faxine were found to be effective in relieving pain and
improving activity.114
EMA401 is an angiotensin II type 2 receptor
antagonist that was evaluated in a multicenter,
randomized, placebo-controlled trial in 183 patients
with postherpetic neuralgia over 28 days and showed
beneﬁt.174 Anand et al175 showed angiotensin 2
immunostaining in 75% of small- to medium-
diameter human dorsal root ganglia neurons and
that this was the major ligand for angiotensin II type
2 receptor.175 Angiotensin 2–mediated angiotensin II
type 2 receptor signaling was reversed by EMA401,
establishing a mechanism for its action in neuropathic
pain.175
Cibinetide (ARA290), a nonhematopoietic peptide
of erythropoietin, interacts selectively with the innate
repair receptor–mediating tissue protection176 and
also antagonizes the transient receptor potential
vanilloid 1 receptor,177 mediating disease-modifying
and analgesic effects, respectively. It has shown14signiﬁcantly increased small nerve ﬁber abundances
in the cornea and skin, with improved neuropathic
pain in patients with DPN178 and sarcoid
neuropathy.179
Tanezumab is a fully humanized anti–nerve growth
factor monoclonal antibody. However, this class of
drugs has a long and checkered history, with the FDA
placing a clinical hold on clinical studies of anti–nerve
growth factor monoclonal antibody in late 2010,
because of reports of serious joint-related adverse
events and sympathetic nerve damage tolerability
concerns. However, the FDA lifted its hold in March
2015, and in 2017 granted fast-track status as a
nonopioid pain medication,180 particularly for hip
and knee osteoarthritis.181 In the only reported
study in DPN, 20 mg of SC tanezumab was
administered on day 1 and week 8 and showed a
reduction in DPN pain but no improvement in
patients' global assessment of pain.182
Vitamin D deﬁciency is associated with paresthesia
and parasympathetic dysfunction183,184 and is highly
prevalent in diabetic populations.185 Shebab et al186
showed that vitamin D deﬁciency is a risk factor forVolume ] Number ]
Z. Iqbal et al.DPN. Furthermore, a meta-analysis in type 2 diabetes
(n ¼ 1484) conﬁrmed a signiﬁcant correlation
between serum vitamin D3 levels and the risk for
DPN.187 An open-label, prospective study conducted
in Pakistan found a single IM-administered dose of
600,000 IU of vitamin D3 provided signiﬁcant pain
relief in painful DPN.188 More data are required
before the role of vitamin D supplementation in
painful DPN is established.International Guidelines for Painful DPN
Five professional bodies have produced expert
guidance on the management of painful diabetic
neuropathy (Table III).50,109,111–113 Pregabalin is rec-
ommended as ﬁrst-line therapy in all 5 guidelines, and
duloxetine is recommended as ﬁrst-line in all of the
guidelines except that from the American Academy of
Neurology, based on only 1 duloxetine trial being
graded as class 1 evidence, due to completion rates
being o80% of those in other trials.50CONCLUSIONS
DPN is common, often misdiagnosed, and inad-
equately treated. DPN accounts for considerable
morbidity and mortality and reduced quality of life.
Clinical recognition is required for allowing timely
symptomatic management to reduce the morbidity
associated with this condition. Glycemic control is
the central component of treatment, but it is difﬁcult
to achieve for many patients. Cardiovascular risk
factors play a major role in the pathogenesis of DPN
and should be intensively controlled with a personal-
ized approach to the patient. The management of pain
remains the key aspect of symptom treatment for
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